04
Nov

Novartis believes its new oncology treatment can make a major difference for patients with multiple myeloma, a blood cancer with a particularly grim prognosis. But first it’ll have to convince a group of independent experts that the drug’s ability to extend survival by a few months outweighs a significant increase in safety risks.

…read more

Source: Novartis gears up for FDA scrutiny with a new blood cancer drug

    

0 No comments